(3S,3'S,4'R,6'R,8'R,8'aR)-6-chloro-8'-(3-chlorophenyl)-6'-(2,2-dimethylpropyl)-3',4'-diphenylspiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]-1',2-dione | 897365-77-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (3S,3'S,4'R,6'R,8'R,8'aR)-6-chloro-8'-(3-chlorophenyl)-6'-(2,2-dimethylpropyl)-3',4'-diphenylspiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]-1',2-dione
• CAS: 897365-77-4
• 化学式: C₃₇H₃₄Cl₂N₂O₃
• 分子量: 625.595
• InChiKey: BVRBFKXTFYXSDB-MLMHKPGRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.4
• 重原子数：
  44
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3S,3'S,4'R,6'R,8'R,8'aR)-6-chloro-8'-(3-chlorophenyl)-6'-(2,2-dimethylpropyl)-3',4'-diphenylspiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]-1',2-dione 在 lead(IV) acetate 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 生成 (2'R,3S,4'R,5'R)-6-chloro-4'-(3-chloro-phenyl)-2'-(2,2-dimethyl-propyl)-2-oxo-1,2-dihydro-spiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (2-morpholin-4-yl-ethyl)-amide
  参考文献：
  名称：

  Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 Interaction

  摘要：

  Potent, specific, non-peptide small-molecule inhibitors of the MDM2-p53 interaction were successfully designed. The most potent inhibitor ( MI-63) has a K-i value of 3 nM binding to MDM2 and greater than 10 000-fold selectivity over Bcl-2/Bcl-xL proteins. MI-63 is highly effective in activation of p53 function and in inhibition of cell growth in cancer cells with wild-type p53 status. MI-63 has excellent specificity over cancer cells with deleted p53 and shows a minimal toxicity to normal cells.

  DOI：

  10.1021/jm051122a
• 作为产物：
  描述：

  6-氯氧化吲哚 在 potassium fluoride on basic alumina 、 4 A molecular sieve 作用下， 以 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 5.17h， 生成 (3S,3'S,4'R,6'R,8'R,8'aR)-6-chloro-8'-(3-chlorophenyl)-6'-(2,2-dimethylpropyl)-3',4'-diphenylspiro[1H-indole-3,7'-4,6,8,8a-tetrahydro-3H-pyrrolo[2,1-c][1,4]oxazine]-1',2-dione
  参考文献：
  名称：

  Structure-Based Design of Potent Non-Peptide MDM2 Inhibitors

  摘要：

  A successful structure-based design of a class of non-peptide small-molecule MDM2 inhibitors targeting the p53-MDM2 protein-protein interaction is reported. The most potent compound 1d binds to MDM2 protein with a Ki value of 86 nM and is 18 times more potent than a natural p53 peptide (residues 16-27). Compound 1d is potent in inhibition of cell growth in LNCaP prostate cancer cells with wild-type p53 and shows only a weak activity in PC-3 prostate cancer cells with a deleted p53. Importantly, 1d has a minimal toxicity to normal prostate epithelial cells. Our studies provide a convincing example that structure-based strategy can be employed to design highly potent, non-peptide, cell-permeable, small-molecule inhibitors to target protein-protein interaction, which remains a very challenging area in chemical biology and drug design.

  DOI：

  10.1021/ja051147z

文献信息

• Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors
  作者：Yujun Zhao、Liu Liu、Wei Sun、Jianfeng Lu、Donna McEachern、Xiaoqin, Li、Shanghai Yu、Denzil Bernard、Philippe Ochsenbein、Vincent Ferey、Jean-Christophe Carry、Jeffrey R. Deschamps、Duxin Sun、Shaomeng Wang

  DOI：10.1021/ja3125417

  日期：2013.5.15

  which affords four diastereomers from a single compound. Our biochemical binding data showed that the stereochemistry in this class of compounds has a major effect on their binding affinities to MDM2, with >100-fold difference between the most potent and the least potent stereoisomers. Our study has led to the identification of a set of highly potent MDM2 inhibitors with a stereochemistry that is different

  阻断 MDM2-p53 蛋白-蛋白相互作用的小分子抑制剂（MDM2 抑制剂）作为一种新的癌症治疗策略正受到强烈追捧。我们之前发表了一系列含有螺环吲哚的化合物作为一类新的 MDM2 小分子抑制剂。我们在此报告了这些螺吲哚中的一些的可逆开环环化反应，该反应从单个化合物提供四种非对映异构体。我们的生化结合数据表明，这类化合物的立体化学对其与 MDM2 的结合亲和力有主要影响，最强和最弱立体异构体之间的差异大于 100 倍。我们的研究已经确定了一组高效的 MDM2 抑制剂，其立体化学不同于我们之前报道的化合物。
• SPIRO-OXINDOLE MDM2 ANTAGONISTS
  申请人：Wang Shaomeng

  公开号：US20120122947A1

  公开（公告）日：2012-05-17

  Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.

  本文提供了关于药物化学领域的化合物、组合物和方法。这里提供的化合物和组合物涉及螺环氧吲哚，其作为p53和MDM2相互作用的拮抗剂，并且它们作为治疗癌症和其他疾病的药物的用途。
• Potent and Orally Active Small-Molecule Inhibitors of the MDM2−p53 Interaction
  作者：Shanghai Yu、Dongguang Qin、Sanjeev Shangary、Jianyong Chen、Guoping Wang、Ke Ding、Donna McEachern、Su Qiu、Zaneta Nikolovska-Coleska、Rebecca Miller、Sanmao Kang、Dajun Yang、Shaomeng Wang

  DOI：10.1021/jm901400z

  日期：2009.12.24

  We report herein the design of potent and orally active small-molecule inhibitors of the MDM2-p53 interaction, Compound 5 binds to MDM2 with a K-i of 0.6 nM, activates p53 at concentrations its low as 40 nM, and potently and selectively inhibits cell growth in tumor cells with wild-type p53 over tumor cells with mutated/deleted p53. Compound 5 has a good oral bioavailability and effectively inhibits tumor growth in the SJSA-1 xenograft model.